Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 6
2003 9
2004 2
2005 7
2006 8
2007 10
2008 7
2009 16
2010 16
2011 11
2012 8
2013 8
2014 9
2015 5
2016 11
2017 9
2018 12
2019 11
2020 8
2021 7
2022 4
2023 4
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Results by year

Filters applied: . Clear all
Page 1
BCL2 inhibition: back to the future!
Dyer MJS, Walter HS. Dyer MJS, et al. Blood. 2024 May 2;143(18):1787-1788. doi: 10.1182/blood.2023023796. Blood. 2024. PMID: 38696193 No abstract available.
Obinutuzumab Versus Rituximab Immunochemotherapy in Previously Untreated iNHL: Final Results From the GALLIUM Study.
Townsend W, Hiddemann W, Buske C, Cartron G, Cunningham D, Dyer MJS, Gribben JG, Phillips EH, Dreyling M, Seymour JF, Grigg A, Trotman J, Lin TY, Hong XN, Kingbiel D, Nielsen TG, Knapp A, Herold M, Marcus R. Townsend W, et al. Among authors: dyer mjs. Hemasphere. 2023 Jun 30;7(7):e919. doi: 10.1097/HS9.0000000000000919. eCollection 2023 Jul. Hemasphere. 2023. PMID: 37404773 Free PMC article.
Computational modeling of DLBCL predicts response to BH3-mimetics.
Cloete I, Smith VM, Jackson RA, Pepper A, Pepper C, Vogler M, Dyer MJS, Mitchell S. Cloete I, et al. Among authors: dyer mjs. NPJ Syst Biol Appl. 2023 Jun 6;9(1):23. doi: 10.1038/s41540-023-00286-5. NPJ Syst Biol Appl. 2023. PMID: 37280330 Free PMC article.
BTK mutations in patients with chronic lymphocytic leukemia receiving tirabrutinib.
Jackson RA, Britton RG, Jayne S, Lehmann S, Cowley CM, Trethewey CS, Smith VM, Schmid R, Fegan C, Walter HS, Dyer MJS. Jackson RA, et al. Among authors: dyer mjs. Blood Adv. 2023 Jul 25;7(14):3378-3381. doi: 10.1182/bloodadvances.2022009366. Blood Adv. 2023. PMID: 37257190 Free PMC article. No abstract available.
Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.
Thompson MC, Harrup RA, Coombs CC, Roeker LE, Pu JJ, Choi MY, Barr PM, Allan JN, Šimkovič M, Leslie L, Rhodes J, Chong EA, Kamdar M, Skarbnik A, Lansigan F, McCall B, Saja K, Dyer MJS, Walter HS, Lefebure M, Thadani-Mulero M, Boyer M, Biondo J, Sail K, Manzoor BS, Furman R, Bantilan KS, Goy A, Feldman T, Labella D, Schuster SJ, Park J, Palomba L, Zelenetz A, Eyre TA, Kater AP, Seymour JF, Mato AR. Thompson MC, et al. Among authors: dyer mjs. Blood Adv. 2022 Aug 9;6(15):4553-4557. doi: 10.1182/bloodadvances.2022007812. Blood Adv. 2022. PMID: 35736670 Free PMC article. No abstract available.
Limitations of Monitoring Disease Progression Using Circulating Tumor DNA in Lymphoma: An Example From Primary Cutaneous DLBCL Leg-type.
Trethewey CS, Walter HS, Alqahtani ANM, Schmid R, Guttery DS, Griffin Y, Ahearne MJ, Saldanha GS, Jayne SPN, Dyer MJS. Trethewey CS, et al. Among authors: dyer mjs. Hemasphere. 2022 Mar 1;6(3):e690. doi: 10.1097/HS9.0000000000000690. eCollection 2022 Mar. Hemasphere. 2022. PMID: 35261967 Free PMC article. No abstract available.
Chronic lymphocytic leukaemia therapy: is less more?
Walter HS, Dyer MJS. Walter HS, et al. Among authors: dyer mjs. Lancet Haematol. 2022 Mar;9(3):e169-e171. doi: 10.1016/S2352-3026(22)00044-8. Lancet Haematol. 2022. PMID: 35240069 No abstract available.
155 results